Lecture Topic 1: Construction and Application of Standardized Stem Cell and Organoid Resource Library

Introduction to the speaker

Dr. Liang Lingmin, Senior researcher at Jinfeng Laboratory and technical director of the Stem Cell Center Resource Library. He presides over the major projects of Chongqing 2025 Biopharmaceutical Technology Innovation Center and has long been committed to the construction of clinical-grade stem cell resources, regulation of pluripotent stem cell differentiation and the development of cell therapy. Successfully established multiple human embryonic stem cell and adult stem cell lines that meet clinical standards, and promoted their directional differentiation into functional cells such as dopamine neural precursor cells, mesenchymal stromal cells, and immune cells, supporting the first domestic clinical research on human embryonic stem cells for the treatment of Parkinson's disease and the approval of multiple INDs. In terms of standardization, we participated in the formulation of the first international standard, the first national standard and multiple group standards in the field of stem cells, and are committed to promoting the development of industry standards.

Stem cells and organoids are core resources for analyzing disease mechanisms, drug screening and regenerative medicine. In May 2026, the "Regulations on the Management of Clinical Research and Clinical Transformation Application of New Biomedical Technologies" will be officially implemented, putting forward higher compliance requirements for the construction of resource libraries. In November 2025, Jinfeng Laboratory was awarded the "National Stem Cell Resource Bank (Chongqing)" and became the first branch bank. This lecture focuses on the entire chain of resource library construction: introducing the necessity and importance of standardized resource library construction, and the strategic positioning of the National Stem Cell Resource Bank (Chongqing) ； Explain the construction elements and paths of the standardized resource library, and share the Jinfeng branch’s 2 million collection capabilities and special directions such as pathological stem cells and plateau stem cells. ； It explains how the resource library empowers drug research and development, organoid precision medicine, and open sharing mechanisms to help the team integrate into the national core system and promote transformation and application in the western region.

Dr. Yao Junjun , Jinfeng Laboratory Stem Cell Center, young scholar. Focusing on stem cell biology and regenerative medicine research, it has accumulated systematic and in-depth technical experience in the isolation and culture, functional analysis and transformation application of neural stem cells, mesenchymal stem cells and microglia. For the first time, the molecular profile of human hippocampal neural stem cells in aging and damaged states was systematically analyzed (eLife, first author) and a new type of microglia was discovered.

Most neurodegenerative diseases (such as multiple sclerosis, Alzheimer's disease, stroke, etc.) are accompanied by significant demyelination damage due to the accumulation of inflammation and toxic proteins in the brain microenvironment. Damage to myelin sheath can lead to interruption of signal conduction and axonal degeneration. However, existing therapies can only alleviate symptoms but cannot reverse the demyelination damage that has occurred. The fundamental reason is that the myelin repair mechanism has not yet been elucidated. Whether there are cell types other than OPC/OLG that can directly participate in myelination regeneration is still a key gap in the field. This study integrated single-cell nuclear transcriptome data from multiple brain regions in patients with a variety of neurodegenerative diseases and identified a previously unrecognized microglia subtype—oligodendrocyte-like microglia (OLM). This subtype retains the identity of microglia while endogenously expressing high levels of key genes of the oligodendrocyte lineage. It is conserved across species and has close spatial proximity and ligand-receptor interactions with oligodendrocytes. ； Functionally, OLM can promote myelin repair in progeria SAMP8 mice and spinal cord injury rats, providing a new endogenous cell resource for cell therapy of demyelinating diseases. It provides an important theoretical basis for the future construction of a cell resource library based on this type of cells and for promoting the clinical translation of myelin repair strategies.